Clinical trial
Safety and Efficacy Clinical Study of SNS-595 in Patients With…
NCT00408603 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00408603 |
|---|---|
| Title | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer |
| Official title | A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Voreloxin Injection |
| Enrollment | 183 |
| Start date | Dec 20, 2006 |
| Primary completion | Jun 9, 2010 |
| Completion | Jun 9, 2010 |
| First posted | Dec 7, 2006 |
| Last update posted | Jul 27, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: